Slaughter and May advises Citi on the HK$930 million primary placing by LifeTech
Slaughter and May, Hong Kong, advised Citigroup Global Markets Limited, as the placing agent, in relation to the placing of 287,320,000 ordinary shares in LifeTech Scientific Corporation (LifeTech). The gross proceeds from the placing were approximately HK$930 million. LifeTech intends to use the net proceeds from the placing for repayment of bank borrowings, funding potential business development, and as general working capital. The placing was completed on 11 December 2020.
LifeTech is a leading supplier of minimally invasive interventional medical devices that treat cardiovascular diseases. The products of LifeTech are marketed in more than 100 countries by over 300 distributors. It has been listed on the Main Board of the Stock Exchange of Hong Kong since 10 November 2011.